5 recruiting, 2 not yet recruiting, 1 active not recruiting. 5 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 1 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Clear Cell Renal Cell Cancer (ccRCC): new trials by email Literature Review of Clear Cell Renal Cell Cancer (ccRCC) trials Research Report on Clear Cell Renal Cell Cancer (ccRCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors 18F-T2 PET/CT - Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC) | Not applicable | Recruiting | Peking University First Hospital | 200 | 2026-04-27 | 2026-05-14 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
| Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02) Core Needle Biopsy, Forceps Biopsy, Punch Biopsy - Immunotherapy, Cancer | Active not recruiting | Elephas | 416 | 2023-06-26 | 2026-06-29 | |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 - Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Recruiting | Lumara Bio Oncologics GmbH | 270 | 2023-03-14 | 2026-08-11 |
| GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | GI Innovation, Inc. | 317 | 2021-08-02 | 2026-10-19 |
Carcinoma, Renal Cell (8) · Carcinoma, Transitional Cell (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Kidney Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Recurrence (2) · Uterine Cervical Neoplasms (2) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Liver Neoplasms (1)
Adenocarcinoma (8) · Carcinoma (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Urologic Diseases (8) · Urologic Neoplasms (8) · Neoplasms (7) · Kidney Neoplasms (5)
Biopsy, Large-Core Needle (1) · Denosumab (1) · Diphosphonates (1) · Ibandronic Acid (1) · Radiotherapy (1) · Zoledronic Acid (1) · lenvatinib (1) · pembrolizumab (1)
Telix Pharmaceuticals (Innovations) Pty Limited (2) · Elephas (1) · Fudan University (1) · GI Innovation, Inc. (1) · Kelly Fitzgerald, MD (1) · Lumara Bio Oncologics GmbH (1) · Peking University First Hospital (1)
United States (4) · Australia (2) · China (1) · France (1) · South Korea (1)
Fred Hausheer, MD, FACP (1) · Kelly Fitzgerald, MD (1) · Meng Liu (1) · Nari Yun, PhD (1)
PMID 22980441, PMID 26706103, PMID 40791544, PMID 41484629
2023 (1), 2025 (1)